Physician profile
Mark E Basiratmand
NPI 1154836153
$3,778.18
in general payments reported to CMS, 2019-2025
15 companies · $1,318 in 2025
The $1,318 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $709 · 2024: $1,751 · 2025: $1,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,778.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $892.47 | 2023-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $792.49 | 2023-2025 | |
| Amgen INC. | $736.08 | 2024-2025 | Repatha, Krystexxa, Otezla |
| Ibsa Pharma INC. | $414.55 | 2023-2024 | Licart, Tirosint, Tirosint |
| Ardelyx, INC. | $286.18 | 2024-2025 | Ibsrela |
| Esperion Therapeutics, INC. | $151.45 | 2024 | Nexletol, Nexlizet |
| Madrigal Pharmaceuticals | $150.00 | 2025 | Rezdiffra |
| Ironwood Pharmaceuticals, INC | $125.00 | 2024 | |
| Lilly USA, LLC | $56.20 | 2025 | Zepbound, Mounjaro |
| Intra-Sana Laboratories | $55.64 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Exact Sciences Corporation | $36.99 | 2023 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $24.36 | 2023 | Farxiga |
| Glaxosmithkline, LLC. | $21.70 | 2025 | Bexsero |
| Kowa Pharmaceuticals America, INC. | $18.00 | 2025 | Zoryve |
| Merck Sharp & Dohme LLC | $17.07 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Basiratmand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.